Dupixent Lawsuits Sought to Be Centralized in Georgia

Plaintiffs in 15 federal lawsuits involving the prescription drug Dupixent (dupilumab) have asked the Judicial Panel on Multidistrict Litigation (“JPML”) to transfer and consolidate all related cases, spread amongst 9 federal districts, to one federal court. Plaintiffs’ lawsuits allege that, as a result of using Dupixent, they developed cutaneous T-cell lymphoma (CTCL).

In February 2026, Levin Papantonio attorneys Brandon L. Bogle and Madison Mougey filed a motion to transfer all related Dupixent cases to the United States District Court for the Northern District of Georgia. The motion notes that more than twenty-five percent of the cases filed to date, the highest number in any district, are currently pending there. Plaintiffs also argue the district is centrally located and convenient for the parties.

According to the motion, the lawsuits share common questions of fact and law, including whether Dupixent increases the risk of CTCL and whether the manufacturers failed to provide adequate warnings. Plaintiffs say centralizing the litigation would promote efficiency, prevent duplicative discovery, and support consistent rulings across the cases.

The motion also points to recent FDA activity regarding Dupixent and CTCL.

Dupixent, also known by its generic name dupilumab, is a prescription medication approved by the FDA to treat moderate to severe eczema, also called atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. The drug works by blocking certain proteins involved in inflammation. Patients, including Plaintiffs, have reported serious side effects, including the development of CTCL, a rare but aggressive form of cancer.

On January 15, 2025, the FDA notified Regeneron that it had identified and begun evaluating a newly identified safety signal regarding dupilumab therapy for atopic dermatitis being associated with an increased risk of cutaneous T-cell lymphoma. The FDA noted it had classified the safety signal as a potential safety risk in December 2024.

On March 31, 2025, the FDA published its quarterly report “Potential Signals of Serious Risks and New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) for the fourth quarter of 2024”, which is available here on the FDA website. In that report, the FDA again referenced dupilumab and cutaneous T-cell lymphoma in connection with potential safety signals.

“Patients trust that the medications prescribed to them have been fully studied and that any serious risks will be clearly disclosed,” said attorney Brandon Bogle of Levin Papantonio. “Defendants marketed Dupixent as safe and effective, even as growing scientific evidence and FDA safety communications raised concerns about a link to CTCL. Patients and their doctors deserve transparency so they can make truly informed decisions about treatment.”

Plaintiffs allege that, despite these developments, Defendants have not implemented appropriate labeling revisions to warn of the risk of CTCL  linked to Dupixent, nor have they taken steps to reduce or eliminate that risk.

Levin Papantonio is investigating claims on behalf of individuals diagnosed with CTCL after using Dupixent. If you or a loved one has been diagnosed with CTCL after using Dupixent, you may have legal options.

To learn more, contact Levin Papantonio for a free and confidential consultation.